12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Savira Pharmaceuticals, Roche deal

Roche exercised its option to take sole development responsibility for Savira's preclinical influenza polymerase inhibitor programs under a June 2012 deal granting Roche exclusive, worldwide rights...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >